Advances in the treatment of tuberculous meningitis

doi:10.3969/j.issn.1000-6621.2019.01.020

Abstract

Abstract:

Tuberculous meningitis (TBM) is the most lethal form of tuberculosis, and its clinical incidence rate is gradually increasing. In the recent years, there are much progress in the treatment of TBM. This article reviewed the related research in the fields of chemotherapy, adjuvant therapy and the treatment of complications. We hope to provide help for the clinical treatment of TBM.

Key words: Tuberculosis, meningeal, Drug therapy, combination, Combined modality therapy, Review literature as topic

Ling-ling SHAO,Hong-fei DUAN. Advances in the treatment of tuberculous meningitis[J]. Chinese Journal of Antituberculosis, 2019, 41(1): 102-106. doi: 10.3969/j.issn.1000-6621.2019.01.020

References 40

[1]	World Health Organization . Global tuberculosis report 2018. Geneva: World Health Organization, 2018.
[2]	李雪莲, 高孟秋 . 结核性脑膜炎患者行脑脊液实验室检测方法的现状与进展. 中国防痨杂志, 2018,40(3):320-340.
[3]	Ramachandran P, Duraipandian M, Nagarajan M , et al. Three chemotherapy studies of tuberculous meningitis in children. Tubercle, 1986,67(1):17-29. doi: 10.1016/0041-3879(86)90028-0 URL pmid: 3715980
[4]	Thwaites G, Fisher M, Hemingway C , et al. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect, 2009,59(3):167-187. doi: 10.1016/j.jinf.2009.06.011 URL pmid: 19643501
[5]	Donald PR . Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb), 2010,90(5):279-292. doi: 10.1016/j.tube.2010.07.002 URL pmid: 20709598
[6]	Savic RM, Ruslami R, Hibma JE , et al. Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children. Clin Pharmacol Ther, 2015,98(6):622-629. doi: 10.1002/cpt.202 URL pmid: 26260983
[7]	Ruslami R, Ganiem AR, Dian S , et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis, 2013,13(1):27-35. doi: 10.1016/S1473-3099(12)70264-5 URL pmid: 23103177
[8]	Heemskerk AD, Bang ND, Mai NT , et al. Intensified antituberculosis therapy in adults with tuberculous meningitis. N Engl J Med, 2016,374(2):124-134. doi: 10.1056/NEJMoa1507062 URL pmid: 26760084
[9]	Rizvi I, Malhotra HS, Garg RK , et al. Fluoroquinolones in the management of tuberculous meningitis: Systematic review and meta-analysis. J Infect, 2018,77(4):261-275.
[10]	Wilkinson RJ, Rohlwink U, Misra UK , et al. Tuberculous Meningitis International Research C. Tuberculous meningitis. Nat Rev Neurol, 2017,13(10):581-598.
[11]	Schnippel K, Ndjeka N, Maartens G , et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. The Lancet Respira-tory Medicine, 2018,6(9):699-706.
[12]	Ferlazzo G, Mohr E, Laxmeshwar C , et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infect Dis, 2018,18(5):536-544.
[13]	Donald PR . Chemotherapy for tuberculous meningitis. N Engl J Med, 2016,374(2):179-181. URL pmid: 9755923
[14]	Thwaites GE, Nguyen DB, Nguyen HD , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med, 2004,351(17):1741-1751. doi: 10.1007/s11910-006-0045-4 URL pmid: 15963328
[15]	Prasad K, Singh MB, Ryan H. Corticosteroids for managing tuberculous meningitis.Cochrane Database Syst Rev, 2016,4: CD002244.
[16]	Thwaites GE, Macmullen-Price J, Tran TH , et al. Serial MRI to determine the effect of dexamethasone on the cerebral pathology of tuberculous meningitis: an observational study. Lancet Neurol, 2007,6(3):230-236. doi: 10.1016/S1474-4422(07)70034-0 URL pmid: 17303529
[17]	Tobin DM, Roca FJ, Oh SF , et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell, 2012,148(3):434-446. doi: 10.1016/j.cell.2011.12.023 URL pmid: 3433720
[18]	Tobin DM, Vary JC, Ray JP , et al. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell, 2010,140(5):717-730. doi: 10.1016/j.cell.2010.02.013 URL pmid: 2907082
[19]	Thuong NT, Heemskerk D, Tram TTB , et al. Leukotriene A4 Hydrolase Genotype and HIV Infection Influence Intracerebral Inflammation and Survival From Tuberculous Meningitis. J Infect Dis, 2017,215(7):1020-1028. doi: 10.1093/infdis/jix050 URL pmid: 28419368
[20]	van Laarhoven A, Dian S, Ruesen C , et al. Clinical parameters, routine inflammatory markers, and LTA4H genotype as predictors of mortality among 608 patients with tuberculous meningitis in Indonesia. J Infect Dis, 2017,215(7):1029-1039. doi: 10.1093/infdis/jix051 URL pmid: 28419315
[21]	Heemskerk AD, Bang ND, Mai NT , et al. Intensified antituberculosis therapy in adults with tuberculous meningitis. N Engl J Med, 2016,374(2):124-134. doi: 10.1056/NEJMoa1507062 URL pmid: 26760084
[22]	Fava VM, Schurr E . Evaluating the impact of LTA4H genotype and immune status on survival from tuberculous meningitis. J Infect Dis, 2017,215(7):1011-1013. doi: 10.1093/infdis/jix052 URL pmid: 28419367
[23]	Kalita J, Misra UK, Nair PP . Predictors of stroke and its significance in the outcome of tuberculous meningitis. J Stroke Cerebrovasc Dis, 2009,18(4):251-258. doi: 10.1016/j.jstrokecerebrovasdis.2008.11.007 URL pmid: 19560677
[24]	Misra UK, Kalita J, Nair PP . Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial. J Neurol Sci, 2010,293(1/2):12-17. doi: 10.1016/j.jns.2010.03.025 URL pmid: 20421121
[25]	Schoeman JF , Janse van Rensburg A, Laubscher JA, et al. The role of aspirin in childhood tuberculous meningitis. J Child Neurol, 2011,26(8):956-962. doi: 10.1177/0883073811398132 URL pmid: 21628697
[26]	Dong X, Li X, Li M , et al. Inhibitory effects of thalidomide on bleomycin-induced pulmonary fibrosis in rats via regulation of thioredoxin reductase and inflammations. Am J Transl Res, 2017,9(10):4390-4401. URL pmid: 5666049
[27]	Schoeman JF, Fieggen G, Seller N , et al. Intractable intracranial tuberculous infection responsive to thalidomide: report of four cases. J Child Neurol, 2006,21(4):301-308.
[28]	Schoeman JF, Andronikou S, Stefan DC , et al. Tuberculous meningitis-related optic neuritis: recovery of vision with thalidomide in 4 consecutive cases. J Child Neurol, 2010,25(7):822-828. doi: 10.1177/0883073809350507 URL pmid: 20519667
[29]	Roberts MT, Mendelson M, Meyer P , et al. The use of thalidomide in the treatment of intracranial tuberculomas in adults: two case reports. J Infect, 2003,47(3):251-255. doi: 10.1016/S0163-4453(03)00077-X URL pmid: 12963389
[30]	Molton JS, Huggan PJ, Archuleta S . Infliximab therapy in two cases of severe neurotuberculosis paradoxical reaction. Med J Aust, 2015,202(3):156-157. URL pmid: 25669480
[31]	赵亚群, 李洪敏, 何秀云 , 等. 早期行脑室腹腔分流术治疗结核性脑积水的可行性研究. 中国防痨杂志, 2015,37(2):157-160. doi: 10.3969/j.issn.1000-6621.2015.02.008 URL
[32]	陈宇, 樊丽超, 陈禹 , 等. 持续腰大池引流在结核性脑膜炎治疗中的应用. 结核病与肺部健康杂志, 2018,7(3):221-224. doi: 10.3969/j.issn.1007-614x.2011.34.002 URL
[33]	姚叶萍 . 腰大池置管持续引流联合鞘内注药治疗结核性脑膜炎的疗效观察. 宁夏医科大学学报, 2015,37(1):81-83. doi: 10.3969/j.issn.1006-2084.2011.12.043 URL
[34]	Goyal P, Srivastava C, Ojha BK , et al. A randomized study of ventriculoperitoneal shunt versus endoscopic third ventriculostomy for the management of tubercular meningitis with hydrocephalus. Childs Nerv Syst, 2014,30(5):851-857. doi: 10.1007/s00381-014-2371-1 URL pmid: 24493368
[35]	Kumar A, Singh K, Sharma V . Surgery in hydrocephalus of tubercular origin: challenges and management. Acta Neurochir (Wien), 2013,155(5):869-873. doi: 10.1007/s00701-013-1658-4 URL pmid: 23504056
[36]	钱增辉, 刘爱华, 汤可 . 结核性脑积水诊治现况及进展. 中华神经医学杂志, 2014,13(9):962-964. doi: 10.3760/cma.j.issn.1671-8925.2014.09.023 URL
[37]	Misra UK, Kalita J, Bhoi SK , et al. A study of hyponatremia in tuberculous meningitis. J Neurol Sci, 2016,367:152-157.
[38]	Sterns RH, Silver SM . Cerebral salt wasting versus SIADH: What difference? J Am Soc Nephrol, 2008,19(2):194-196. doi: 10.1681/ASN.2007101118 URL pmid: 18216309
[39]	Francony G, Fauvage B, Falcon D , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Crit Care Med, 2008,36(3):795-800. doi: 10.1097/CCM.0B013E3181643B41 URL pmid: 18209674
[40]	Gu J, Huang H, Huang Y , et al. Hypertonic saline or mannitol for treating elevated intracranial pressure in traumatic brain injury: a meta-analysis of randomized controlled trials. Neurosurg Rev, 2018. doi: 10.1007/s10143-018-0991-8 URL